GT201600255A - Compuestos, composición farmacéutica y su uso para tratar enfermedades neurodegenerativas - Google Patents
Compuestos, composición farmacéutica y su uso para tratar enfermedades neurodegenerativasInfo
- Publication number
- GT201600255A GT201600255A GT201600255A GT201600255A GT201600255A GT 201600255 A GT201600255 A GT 201600255A GT 201600255 A GT201600255 A GT 201600255A GT 201600255 A GT201600255 A GT 201600255A GT 201600255 A GT201600255 A GT 201600255A
- Authority
- GT
- Guatemala
- Prior art keywords
- neurodegenerative diseases
- compounds
- pharmaceutical composition
- treat neurodegenerative
- sigma
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/50—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/10—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Indole Compounds (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A NUEVOS COMPUESTOS, INCLUYENDO SUS SALES Y SOLVATOS FARMACÉUTICAMENTE ACEPTABLES, QUE SON MODULADORES, VENTAJOSAMENTE AGOSNISTAS DEL RECEPTOR SIGMA-1 (SIGMA-1, ORL O SIG-IR) Y SON ÚTILES COMO COMPUESTOS TERAPÉUTICOS, PARTICULARMENTE EN EL TRATAMIENTO, LA PREVENCIÓN Y/O DIAGNÓSTICO DE ENFERMEDADES NEURODEGENERATIVAS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14305919 | 2014-06-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT201600255A true GT201600255A (es) | 2019-09-20 |
Family
ID=50982878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT201600255A GT201600255A (es) | 2014-06-16 | 2016-12-08 | Compuestos, composición farmacéutica y su uso para tratar enfermedades neurodegenerativas |
Country Status (29)
Country | Link |
---|---|
US (3) | US10179761B2 (es) |
EP (1) | EP3154934B1 (es) |
JP (1) | JP6704355B2 (es) |
KR (1) | KR20170041662A (es) |
CN (1) | CN106795100B (es) |
AU (1) | AU2015276256B2 (es) |
BR (1) | BR112016029571A2 (es) |
CA (1) | CA2951438C (es) |
CL (1) | CL2016003230A1 (es) |
CO (1) | CO2017000211A2 (es) |
CR (1) | CR20160581A (es) |
DO (1) | DOP2016000325A (es) |
EA (1) | EA031123B1 (es) |
EC (1) | ECSP16094286A (es) |
ES (1) | ES2880313T3 (es) |
GT (1) | GT201600255A (es) |
IL (1) | IL249440B (es) |
MA (1) | MA39533B1 (es) |
MX (1) | MX2016016769A (es) |
MY (1) | MY183757A (es) |
PE (2) | PE20170518A1 (es) |
PH (1) | PH12016502480A1 (es) |
PL (1) | PL3154934T3 (es) |
PT (1) | PT3154934T (es) |
SG (1) | SG11201610478YA (es) |
TN (1) | TN2016000550A1 (es) |
UA (1) | UA123041C2 (es) |
WO (1) | WO2015193255A1 (es) |
ZA (1) | ZA201608558B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI744300B (zh) * | 2016-03-23 | 2021-11-01 | 里爾中央醫學中心 | 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途 |
WO2024033399A1 (en) | 2022-08-10 | 2024-02-15 | Institut National de la Santé et de la Recherche Médicale | Sigmar1 ligand for the treatment of pancreatic cancer |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2241498A (en) * | 1940-11-25 | 1941-05-13 | Champ Items Inc | Method of manufacturing oil shields for internal combustion engines |
US2441498A (en) * | 1943-07-15 | 1948-05-11 | Astra Apotekarnes Kem Fab | Alkyl glycinanilides |
GB1307250A (en) * | 1970-06-16 | 1973-02-14 | May & Baker Ltd | Benzene derivatives |
DE2438288A1 (de) * | 1974-08-09 | 1976-02-19 | Knoll Ag | Neue antiarrhythmika |
US4448776A (en) | 1981-02-12 | 1984-05-15 | Karl Bucher | Method of using certain substituted aliphatic secondary amines or their salts for easing breathing |
JPH02138162A (ja) * | 1988-11-19 | 1990-05-28 | Mitsubishi Kasei Corp | N−フェニルアルキル置換−β−アミノ酸アミド誘導体 |
AU2159692A (en) * | 1991-06-06 | 1993-01-12 | G.D. Searle & Co. | N-(arylethyl)-n-alkyl-2-(1-pyrrolidinyl)ethylamine derivatives for cns disorders |
JPH07188139A (ja) * | 1993-12-24 | 1995-07-25 | Kirin Brewery Co Ltd | アミド化合物 |
FR2729146A1 (fr) * | 1995-01-06 | 1996-07-12 | Smithkline Beecham Lab | Nouveaux derives d'amine, leur procede de preparation et leur utilisation en tant que medicaments et notamment en tant qu'agents anti-arythmiques |
ATE467616T1 (de) * | 2003-04-11 | 2010-05-15 | High Point Pharmaceuticals Llc | Verbindungen mit aktivität an der 11beta- hydroxasteroiddehydrogenase |
SE0301446D0 (sv) | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | New Compounds |
KR20070092740A (ko) * | 2004-12-15 | 2007-09-13 | 바이엘 쉐링 파마 악티엔게젤샤프트 | 메타-치환된 티아졸리디논, 이의 제조 방법 및의약으로서의 용도 |
AU2008338368A1 (en) * | 2007-12-19 | 2009-06-25 | Wyeth Llc | 4-imidazolidinones as Kv1.5 potassium channel inhibitors |
WO2012177618A1 (en) * | 2011-06-20 | 2012-12-27 | Emory University | Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto |
US20130274233A1 (en) * | 2012-04-03 | 2013-10-17 | President And Fellow Of Harvard College | Modulators of hedgehog signaling pathway |
-
2015
- 2015-06-15 MA MA39533A patent/MA39533B1/fr unknown
- 2015-06-15 BR BR112016029571A patent/BR112016029571A2/pt not_active Application Discontinuation
- 2015-06-15 PL PL15730461T patent/PL3154934T3/pl unknown
- 2015-06-15 JP JP2016573483A patent/JP6704355B2/ja active Active
- 2015-06-15 EP EP15730461.9A patent/EP3154934B1/en active Active
- 2015-06-15 EA EA201790020A patent/EA031123B1/ru not_active IP Right Cessation
- 2015-06-15 AU AU2015276256A patent/AU2015276256B2/en not_active Ceased
- 2015-06-15 PT PT157304619T patent/PT3154934T/pt unknown
- 2015-06-15 CA CA2951438A patent/CA2951438C/en active Active
- 2015-06-15 CN CN201580032317.6A patent/CN106795100B/zh active Active
- 2015-06-15 UA UAA201700333A patent/UA123041C2/uk unknown
- 2015-06-15 WO PCT/EP2015/063370 patent/WO2015193255A1/en active Application Filing
- 2015-06-15 ES ES15730461T patent/ES2880313T3/es active Active
- 2015-06-15 KR KR1020167036029A patent/KR20170041662A/ko not_active Application Discontinuation
- 2015-06-15 SG SG11201610478YA patent/SG11201610478YA/en unknown
- 2015-06-15 CR CR20160581A patent/CR20160581A/es unknown
- 2015-06-15 US US15/317,742 patent/US10179761B2/en active Active
- 2015-06-15 PE PE2016002712A patent/PE20170518A1/es not_active Application Discontinuation
- 2015-06-15 TN TN2016000550A patent/TN2016000550A1/en unknown
- 2015-06-15 MY MYPI2016002188A patent/MY183757A/en unknown
- 2015-06-15 MX MX2016016769A patent/MX2016016769A/es unknown
-
2016
- 2016-12-07 IL IL249440A patent/IL249440B/en active IP Right Grant
- 2016-12-08 GT GT201600255A patent/GT201600255A/es unknown
- 2016-12-12 ZA ZA2016/08558A patent/ZA201608558B/en unknown
- 2016-12-12 PH PH12016502480A patent/PH12016502480A1/en unknown
- 2016-12-13 DO DO2016000325A patent/DOP2016000325A/es unknown
- 2016-12-14 EC ECIEPI201694286A patent/ECSP16094286A/es unknown
- 2016-12-15 CL CL2016003230A patent/CL2016003230A1/es unknown
-
2017
- 2017-01-10 CO CONC2017/0000211A patent/CO2017000211A2/es unknown
-
2018
- 2018-03-13 PE PE2018000386A patent/PE20181053A1/es unknown
- 2018-11-30 US US16/205,637 patent/US10844008B2/en active Active
-
2020
- 2020-10-22 US US17/077,530 patent/US20210040034A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT201600215A (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4 | |
CO2017002532A2 (es) | Indazoles sustituidos con bencilo como inhibidores de bub1 | |
CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
BR112016018555A8 (pt) | Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1 | |
ECSP17018120A (es) | Triazolopirazinonas como inhibidores de pde1 | |
CL2016001364A1 (es) | Moduladores de ror gamma (rory) | |
ECSP16078782A (es) | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados | |
UY36224A (es) | Compuestos tricíclicos de imidazo-pirimidinona | |
BR112016018062A8 (pt) | compostos terapêuticos, composição farmacêutica e usos | |
ECSP17074645A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
MX2016015630A (es) | Nuevos compuestos. | |
EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
CL2019001329A1 (es) | Composiciones farmacéuticas moduladoras del receptor 7 de 5-hidroxitritpina y métodos de uso. | |
MX2017005484A (es) | Compuestos antagonistas del receptor de dopamina d3. | |
DOP2016000212A (es) | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados | |
DOP2016000311A (es) | Nuevos compuestos | |
CR20170090A (es) | Derivados de terahidroquinolina como inhibidores del bromodominio | |
EA201692020A1 (ru) | Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях | |
CR20160529A (es) | Composiciones farmacéuticas para tratar enfermedades infecciosas | |
CL2016002779A1 (es) | Composición para el cuidado de la piel | |
CL2016002321A1 (es) | Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios. | |
DOP2016000263A (es) | Quinazolin-thf-aminas halogenadas como inhibidores de pde1 | |
GT201600255A (es) | Compuestos, composición farmacéutica y su uso para tratar enfermedades neurodegenerativas | |
CL2020000812A1 (es) | Semaglutida en la terapia médica. | |
ECSP16071574A (es) | Hexahidrofuropirroles como inhibidores de pde1 |